Literature DB >> 17082489

Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease.

Hidenori Koyama1, Tetsuo Shoji, Shinya Fukumoto, Kayo Shinohara, Takuhito Shoji, Masanori Emoto, Katsuhito Mori, Hideki Tahara, Eiji Ishimura, Ryusuke Kakiya, Tsutomu Tabata, Hiroshi Yamamoto, Yoshiki Nishizawa.   

Abstract

OBJECTIVE: Receptor for advanced glycation end-products (RAGE) is involved in diabetic vascular complications. We have recently shown that plasma endogenously secretory RAGE (esRAGE), an alternatively spliced form of RAGE, is closely associated with metabolic syndrome and atherosclerosis. Here, we evaluated if plasma esRAGE is a predictor of cardiovascular mortality in a cohort of 206 (171 nondiabetic) patients with end-stage renal diseases (ESRD). METHODS AND
RESULTS: The cohort was followed for a median of 111 months, and 74 deaths including 34 cardiovascular deaths were recorded. Plasma esRAGE was measured at baseline. Cumulative incidence of cardiovascular death by Kaplan-Meier estimation was significantly higher in subjects in the lowest tertile of plasma esRAGE than those in the middle or the highest tertile both in all and nondiabetic subjects alone. In all subjects, as compared with the lowest tertile of plasma esRAGE, the hazards ratios for the highest and middle tertile were 0.40 (95% CI, 0.18 to 0.89) and 0.26 (0.10 to 0.66), respectively. The higher risk for lower esRAGE was still significant even after adjusted either with body mass index, hypertension, dyslipidemia and vascular complications, but was confounded by age and diabetes.
CONCLUSIONS: Low circulating esRAGE is a predictor for cardiovascular mortality in ESRD patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17082489     DOI: 10.1161/01.ATV.0000251502.88818.4b

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  27 in total

Review 1.  Advanced glycation end products, diabetes and ageing.

Authors:  N Nass; B Bartling; A Navarrete Santos; R J Scheubel; J Börgermann; R E Silber; A Simm
Journal:  Z Gerontol Geriatr       Date:  2007-10       Impact factor: 1.281

Review 2.  Soluble RAGEs - Prospects for treating & tracking metabolic and inflammatory disease.

Authors:  Ann Marie Schmidt
Journal:  Vascul Pharmacol       Date:  2015-06-27       Impact factor: 5.773

3.  Alternatively spliced RAGEv1 inhibits tumorigenesis through suppression of JNK signaling.

Authors:  Anastasia Z Kalea; Fiona See; Evis Harja; Maria Arriero; Ann Marie Schmidt; Barry I Hudson
Journal:  Cancer Res       Date:  2010-06-22       Impact factor: 12.701

4.  Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes.

Authors:  M C Thomas; J Söderlund; M Lehto; V-P Mäkinen; J L Moran; M E Cooper; C Forsblom; P-H Groop
Journal:  Diabetologia       Date:  2011-05-24       Impact factor: 10.122

5.  Endogenous secretory receptor for advanced glycation end products is associated with low serum interleukin-1 receptor antagonist and elevated IL-6 in older community-dwelling adults.

Authors:  Candace L Crasto; Richard D Semba; Kai Sun; Mansi Dalal; Anna Maria Corsi; Stefania Bandinelli; Jack M Guralnik; Luigi Ferrucci
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2011-02-28       Impact factor: 6.053

6.  Effects of atorvastatin on progression of diabetic nephropathy and local RAGE and soluble RAGE expressions in rats.

Authors:  Lin Lu; Wen-Hui Peng; Wei Wang; Ling-Jie Wang; Qiu-Jing Chen; Wei-Feng Shen
Journal:  J Zhejiang Univ Sci B       Date:  2011-08       Impact factor: 3.066

7.  Advanced glycation end products and their circulating receptors predict cardiovascular disease mortality in older community-dwelling women.

Authors:  Richard D Semba; Luigi Ferrucci; Kai Sun; Justine Beck; Mansi Dalal; Ravi Varadhan; Jeremy Walston; Jack M Guralnik; Linda P Fried
Journal:  Aging Clin Exp Res       Date:  2009-04       Impact factor: 3.636

Review 8.  Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response.

Authors:  Shi Fang Yan; Ravichandran Ramasamy; Ann Marie Schmidt
Journal:  J Mol Med (Berl)       Date:  2009-02-03       Impact factor: 4.599

9.  Visfatin and endogenous secretory receptor for advanced glycation end-products in diabetic type 2 and non-diabetic patients undergoing intermittent hemodialysis.

Authors:  Leszek Niepolski; Alicja E Grzegorzewska; Monika Młot-Michalska
Journal:  Int Urol Nephrol       Date:  2009-01-31       Impact factor: 2.370

10.  Endogenous Secretory RAGE as a Novel Biomarker for Metabolic Syndrome and Cardiovascular Diseases.

Authors:  Hidenori Koyama; Hiroshi Yamamoto; Yoshiki Nishizawa
Journal:  Biomark Insights       Date:  2007-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.